Vivatmo proTM EU-study: FeNO Monitoring in Asthmatic Patients Responding to ICS Treatment

Launched by BOSCH HEALTHCARE SOLUTIONS GMBH · Sep 21, 2022

Keywords

ClinConnect Summary

Subjects will be screened, enrolled and tested at Study Visit #1 and then prescribed inhaled corticosteroid (ICS) treatment as per routine clinical care. Subjects will return for Study Visit #2 in two weeks and repeat fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro,

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject is 7 to 80 years of age.
• • 2. Has asthma
• • 3. Has been identified as a candidate for inhaled corticosteroid (ICS) treatment
• • 4. Is willing and able to perform Vivatmo pro™ testing
• Exclusion Criteria:
• • 1. Subject has used corticosteroids prior to enrollment.
• • 2. Subject has other current serious medical conditions
• • 3. Subject has not been clinically stable for at least 2 weeks prior to the study
• • 4. Subject is unwilling or unable to perform Vivatmo pro testing